BB BIOTECH AG: Innovative biotech companies lead efforts in global challenge
Media Relations Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00 Tanja Chicherio, email@example.com
TE Communications AG, St. Leonhard-Strasse 45, 9001 St. Gallen, Switzerland, tel. +41 79 423 22 28 Thomas Egger, firstname.lastname@example.org
Company profile BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are mainly located in the US and Western Europe. BB Biotech is one of the leading investors in this sector. BB Biotech builds on the long-standing experience of its distinguished Board of Directors and on the fundamental analysis of the experienced Investment Management Team of Bellevue Asset Management AG when making its investment decisions.
Disclaimer This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.
Composition of BB Biotech's portfolio as of June 30, 2020 (in % of securities, rounded values)
Ionis Pharmaceuticals 11.5% Neurocrine Biosciences 8.9% Incyte 7.6% Vertex Pharmaceuticals 6.7% Agios Pharmaceuticals 5.3% Argenx SE 5.2% Moderna 5.2% Esperion Therapeutics 4.8% Alnylam Pharmaceuticals 4.7% Halozyme Therapeutics 4.4% Alexion Pharmaceuticals 3.6% Macrogenics 3.1% Myokardia 2.8% Myovant Sciences 2.4% Radius Health 2.4% Intra-Cellular Therapies 2.3% Exelixis 1.7% Fate Therapeutics 1.6% Nektar Therapeutics 1.5% Crispr Therapeutics 1.5% Black Diamond Therapeutics 1.5% Sage Therapeutics 1.5% Arvinas 1.3% Scholar Rock Holding 1.2% Molecular Templates 1.2% Sangamo Therapeutics 0.9% Voyager Therapeutics 0.8% Intercept Pharmaceuticals 0.8% Generation Bio Co. 0.8% Wave Life Sciences 0.7% Homology Medicines 0.7% Kezar Life Sciences 0.5% G1 Therapeutics 0.4% Cidara Therapeutics 0.3% Akcea Therapeutics 0.2% Bristol-Myers Squibb - CVR 0.1% Alder Biopharmaceuticals - CVR 0.1% Total securities CHF 3 794.6 mn Other assets CHF 36.2 mn Other payables CHF (204.5) mn Net Asset Value CHF 3 626.3 mn
24.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: BB BIOTECH AG Schwertstrasse 6 8200 Schaffhausen
Switzerland Phone: +41 52 624 08 45 E-mail: email@example.com Internet: www.bbbiotech.ch ISIN: CH0038389992 WKN: A0NFN3 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX EQS News ID: 1100739 End of News DGAP News Service